NCT07145814 is a NA clinical trial of dexmedetomidine 0.3 µg/kg/h in Acute Lung Injury(ALI), sponsored by People's Hospital of Guangxi Zhuang Autonomous Region.

Who is sponsoring NCT07145814?

NCT07145814 is sponsored by People's Hospital of Guangxi Zhuang Autonomous Region.

What drugs are being tested in NCT07145814?

Interventions in NCT07145814: dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline.

What condition does NCT07145814 study?

NCT07145814 studies Acute Lung Injury(ALI).

Is NCT07145814 still recruiting?

NCT07145814 is currently completed. Last updated 28 August 2025.

Last reviewed 2025-08-28 · How we verify

NCT07145814

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexmedetomidine Dose-Dependent on Lung Function and AQP1 in One-Lung Ventilation Surgery

Completed NA Last updated 28 August 2025

What this trial tests

NA trial testing dexmedetomidine 0.3 µg/kg/h in Acute Lung Injury(ALI) in 60 participants. Completed in 29 March 2019.

Timeline

5 January 2018

Primary endpoint
29 March 2019

29 March 2019

Quick facts

Lead sponsor	People's Hospital of Guangxi Zhuang Autonomous Region
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	60
Start date	5 January 2018
Primary completion	29 March 2019
Estimated completion	29 March 2019
Sites	1 location across China

Drugs / interventions tested

dexmedetomidine 0.3 µg/kg/h — full drug profile →
dexmedetomidine 0.5 µg/kg/h
0.9 % saline

Conditions studied

Acute Lung Injury(ALI) — all drugs for Acute Lung Injury(ALI) →

Sponsor

People's Hospital of Guangxi Zhuang Autonomous Region

Who can join

Adults 40 to 70, any sex, with Acute Lung Injury(ALI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial evaluated the dose-dependent effects of dexmedetomidine (DEX) on pulmonary function and aquaporin-1 (AQP1) expression during one-lung ventilation (OLV) in thoracoscopic surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Lung Injury(ALI)

Currently open trials in the same condition.

NCT06853223 — This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction · Phase 2 · recruiting
NCT07070362 — Digital Early Warning System for Acute Lung Injury in Liver Surgery · recruiting

Other People's Hospital of Guangxi Zhuang Autonomous Region trials

Trials by the same sponsor.

NCT04954521 — Anlotinib for Hepatocellular Carcinoma · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07145814 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by People's Hospital of Guangxi Zhuang Autonomous Region
Last refreshed: 28 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07145814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing